Revised Audited Financial Result for the Quarter and Year ended 31st March, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma Ltd (BSE: 524516) filed revised audited results for FY25. Revenue from operations stood at zero across all reporting periods, with total income of Rs. 66.14 lacs in FY25 vs Rs. 13.05 lacs in FY24, coming entirely from 'other income'. The company swung to a profit after tax of Rs. 40.41 lacs from a loss of Rs. 5.91 lacs in FY24, with basic EPS of Rs. 0.64 vs Rs. (0.10). A private placement of 74.43 lakh equity shares lifted share capital from Rs. 589 lacs to Rs. 1,397.02 lacs and boosted investments to Rs. 2,135.66 lacs and cash equivalents to Rs. 285.73 lacs. Total assets expanded sharply from Rs. 132.61 lacs to Rs. 2,560.02 lacs. The statutory auditor issued an unmodified opinion but flagged an Emphasis of Matter on unconfirmed loans and advances of Rs. 128.26 lacs whose recoverability could not be verified.
The profit turnaround is driven mainly by investment/income returns on freshly raised capital rather than any core business activity, as operational revenue remains nil. The auditor's emphasis on unrecoverable loans is a red flag for shareholders, even though the balance sheet has been strengthened by the preferential allotment.